Septerna (NASDAQ:SEPN) Reaches New 1-Year Low – Time to Sell?

Shares of Septerna, Inc. (NASDAQ:SEPN) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $15.10 and last traded at $15.45, with a volume of 215 shares changing hands. The stock had previously closed at $15.61.

Analysts Set New Price Targets

SEPN has been the subject of several recent research reports. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. Cantor Fitzgerald began coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 target price for the company. TD Cowen started coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating on the stock. Finally, Wells Fargo & Company assumed coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company.

Septerna Price Performance

The stock’s fifty day simple moving average is $21.14.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in Septerna during the 4th quarter worth about $872,000. Rhumbline Advisers acquired a new position in shares of Septerna during the fourth quarter worth approximately $458,000. SG Americas Securities LLC bought a new stake in shares of Septerna during the fourth quarter valued at approximately $185,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $32,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.